Format

Send to

Choose Destination
Curr Gene Ther. 2017;17(4):320-326. doi: 10.2174/1566523218666171129204926.

The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy.

Author information

1
Department of Ophthalmology Shiyan, Hubei University of Medicine - Taihe Hospital, Hubei. China.
2
Department of Ophthalmology, Tongji Medical College, Huazhong University of Science and Technology - Tongji Hospital, Wuhan Shi. China.

Abstract

INTRODUCTION:

Leber's Optic Hereditary Neuropathy (LHON) is a common cause of teenaged blindness in both eyes for which there is currently no effective treatment. In 1871, the German ophthalmologist Theodor Leber was the first to describe the clinical characteristics of his namesake disease, and through unremitting efforts over the past 100 years, researchers have continued to increase their understanding of LHON. In recent years, using gene therapy, several groups have obtained breakthroughs in the treatment of the disease.

CONCLUSION:

In this article, we will review the challenging journey that researchers faced towards our current understanding of LHON, and describe the transition of gene therapy research for LHON from the bench to bedside.

KEYWORDS:

Allotopic expression technology; Gene therapy; Leber's optic hereditary neuropathy; MT-ND4; Mitochondrial disease; Translational medicine

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center